Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

With their help, we were able to identify a specific TMEM16F mutation which is common in Ashkenazi Jews in general ... new ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

According to recent research, astrocyte cell transplantation could revolutionize treatments for neurological disorders such ...

Chronic fatigue isn’t always a result of lifestyle factors—it can be a signal from your nervous system that something is off ...

According to the researchers, this mutation increases TMEM16F activity, which impacts how cells release substances from their membranes. The faulty alpha-synuclein is then picked up by nearby healthy ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Common Degenerative Brain Disease May Begin to Develop in Middle ... In the future, the discovery may be used in treatment for Parkinson's ...

This affordable and eco-friendly treatment could be available in pill ... functioning and could be life-threatening. The most ...

Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...